Clinical Trial Update: Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the combination of atezolizumab and cabozantinib for recurrent glioblastoma and recurrent gliosarcoma. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Cabometyx (cabozantinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1, Phase 2 | Status: RECRUITING